Postpartum readmission for maternal infection or neonatal adverse events in women randomised to outpatient balloon versus inpatient prostaglandin for induction of labour: a post-trial follow up study
Authors:
Open Access
- 20 April 2026
- journal article
- research article
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1) , 431
Abstract
Background: Induction of labour is common, and much has been studied about different methods and clinical outcomes for mothers and babies. However, many trials follow outcomes only until hospital discharge. The recently published OBLIGE multicentre randomised controlled trial of 1087 participants found no differences in adverse events for mothers or their babies in groups randomised at term to outpatient balloon catheter versus inpatient vaginal prostaglandin E2. The aim of this analysis was to evaluate maternal and neonatal readmissions from hospital discharge to six weeks after birth. Methods: A post-trial follow up of the OBLIGE trial. The clinical records of a subset of participants for whom notes were accessible were reviewed (564 mothers and 477 babies). The primary outcome was maternal readmission to hospital up to six weeks after birth (including a hospital visit of 3 h or more) for infection requiring antibiotics. The secondary outcome was neonatal readmission to hospital up to six weeks after birth (including a hospital visit of 3 h or more) for any reason. Results: Of women randomised to outpatient balloon, 6.3% were readmitted with an infection compared to 6.5% in the inpatient prostaglandin group ( p = 0.99). Of babies born to mothers randomised to outpatient balloon, 10.2% were readmitted compared to 11.7% in the inpatient prostaglandin group ( p = 0.59). Conclusions: In this subset of participants in the OBLIGE trial, there were no differences in maternal readmission for infection, or neonatal admission for any reason, up to six weeks after birth. Consideration of readmission risk for mothers and babies after outpatient balloon induction of labour does not seem to be a reason not to routinely offer outpatient balloon induction of labour. Trial registration: The OBLIGE trial was registered with the Australia New Zealand Clinical Trials Registry (ANZCTR) on 06/06/2016 (ACTRN: 12,616,000,739,415). https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370330&isReview=trueKeywords
Funding Information
- Linköpings Universitet
This publication has 31 references indexed in Scilit:
- Outpatient balloon catheter vs inpatient prostaglandin for induction of labor: a randomized trialAmerican Journal of Obstetrics & Gynecology MFM, 2023
- Balloon catheters versus vaginal prostaglandins for labour induction (CPI Collaborative): an individual participant data meta-analysis of randomised controlled trialsThe Lancet, 2022
- Readmission of late preterm and term neonates in the neonatal periodClinics, 2022
- Maternal and Neonatal Outcomes in Nulliparous Participants Undergoing Labor Induction by Cervical Ripening MethodAmerican Journal of Perinatology, 2021
- Outpatient versus inpatient balloon catheter insertion for labor induction: A systematic review and meta-analysis of randomized controlled trialsJournal of Gynecology Obstetrics and Human Reproduction, 2020
- Determinants of Neonatal Readmission in Healthy Term Infants: Results from a Nested Case–Control StudyAmerican Journal of Perinatology, 2020
- Evaluation of a Transcervical Foley Catheter as a Source of InfectionObstetrics & Gynecology, 2015
- Global causes of maternal death: a WHO systematic analysisThe Lancet Global Health, 2014
- Risk of selected postpartum infections after cesarean section compared with vaginal birth: A five‐year cohort study of 32,468 womenActa Obstetricia et Gynecologica Scandinavica, 2009
- Do mechanical methods of cervical ripening increase infectious morbidity? A systematic reviewAmerican Journal of Obstetrics and Gynecology, 2008